NC
IMPL

NewSquare Capital’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

NewSquare Capital’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20
Closed -$25 – 933
2023
Q2 		$25 Hold
20
– – ﹤0.01% 834
2023
Q1 		$28 Hold
20
– – ﹤0.01% 862
2022
Q4 		$75 Buy
+20
New +$73 ﹤0.01% 778

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

NewSquare Capital's IMPL Position: Q3 2023 in Review

NewSquare Capital sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q3 2023, closing a stake of 20 shares — an estimated $25 sold.

NewSquare Capital first reported a position in IMPL in Q4 2022 and held it in 3 quarters. The position peaked at $75 in Q4 2022. 32 funds tracked by Wall St. Rank hold IMPL as of Q3 2023.

  • NewSquare Capital reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 20 Impel Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $25.
  • NewSquare Capital first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Impel Pharmaceuticals Inc. Common Stock position peaked at $75 in Q4 2022.
  • 32 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.